Cervical Cancer Screening Portfolio
Evolving methods, one goal: the prevention of cervical cancer
Comprehensive capabilities. Breakthrough performance.
Delivering efficiency, flexibility and performance to meet your laboratories' evolving molecular diagnostic needs.
The BD Onclarity™ HPV Assay provides extended high-risk HPV genotyping results beyond 16 and 18, to support risk stratification and enhanced patient management
Minimal time at the instrument
|Current||Single-phase circuit 15 A|
|Temperature||18°C – 27°C / 64.4°F – 80.6°F|
|Humidity||20% to 80%|
|Altitude||Up to 2,000 m (6,562 ft)|
|Noise metrics||< 67 dB|
|Specimen collection type||BD SurePath™ Liquid-based Pap Test Vials
BD Molecular Aliquot Tubes
BD Onclarity™ HPV Liquid-based Cytology (LBC) Specimen
|Reagent/consumable capacity||BD COR™ GX Instrument: 180 HPV tests; 1,056 tips (11 tip trays)
BD COR™ PX Instrument: 35 racks; 192 tips (2 trays; buffer)
|Waste capacity||Solid: 960 conversions (24 hours)
Liquid: 2,160 tests (3 days)
*Capacity and throughput may vary based on specimen types.